Psilocybin, the active compound in psychedelic mushrooms, shows genuine promise for treating depression, with some clinical trials reporting remission rates roughly double those of a leading antidepressant. But this isn’t a supplement you pick up at a health store. The most encouraging results come from carefully supervised therapeutic settings, and psilocybin remains a controlled substance without approved medical use in the United States. Here’s what the science actually shows so far.
What Psilocybin Does in the Brain
When you ingest psilocybin, your body quickly converts it into its active form, which binds to serotonin receptors in the brain. Serotonin is the same chemical messenger that conventional antidepressants target, but psilocybin interacts with it in a fundamentally different way. Rather than gradually increasing serotonin levels over weeks the way SSRIs do, psilocybin directly stimulates specific serotonin receptors, triggering a cascade of changes in a matter of hours.
The most significant of those changes appears to be a burst of new connections between brain cells. Animal research has found that a single dose of psilocybin increases synaptic density, essentially giving neurons more points of contact with each other. Depression is associated with a loss of these connections, particularly in brain regions involved in mood and flexible thinking. By prompting the brain to build new ones, psilocybin may help break rigid patterns of negative thought. This growth of new neural connections, sometimes called neuroplasticity, is now considered a leading explanation for why the antidepressant effects can last weeks or months after a single dose.
Clinical Trial Results
The most closely watched evidence comes from a head-to-head trial published in the New England Journal of Medicine comparing psilocybin therapy to escitalopram, one of the most commonly prescribed SSRIs. Over six weeks, 70% of participants in the psilocybin group showed a meaningful response to treatment, compared with 48% in the escitalopram group. Even more striking, 57% of the psilocybin group achieved full remission of their depression, versus 28% on the SSRI. That said, the primary statistical measure of the trial did not reach significance, meaning the difference could partially reflect chance. The results are encouraging but not yet definitive.
Separate large trials have tested psilocybin specifically in people with treatment-resistant depression, meaning they hadn’t responded to at least two prior antidepressants. These trials tracked participants for 12 weeks after a single dose, measuring both initial response and whether improvements held over time. The fact that a single administration can produce effects lasting months is what distinguishes psilocybin from virtually every other psychiatric treatment, which typically requires daily dosing.
How Psilocybin Therapy Works in Practice
The clinical results don’t come from simply taking a pill. Every major trial has paired the drug with a structured therapeutic process built around three phases: preparation, dosing, and integration.
In preparation sessions, a therapist reviews your history, explains what to expect, and builds a working relationship with you. Researchers emphasize that your mindset going in and the physical environment around you, sometimes called “set and setting,” significantly shape the outcome. This isn’t a formality. Trials treat it as a core part of the intervention.
The dosing session itself lasts about six to eight hours. You take the psilocybin in a comfortable, controlled room with at least one therapist present the entire time. Rather than talking through your problems, you’re encouraged to turn your attention inward and let the psychedelic experience unfold. The therapist is there for safety and support, not to guide a conversation.
Afterward, integration sessions help you make sense of whatever emerged during the experience. You and your therapist work together to identify insights and translate them into new ways of thinking about your life and mental state. Many researchers believe this integration work is what turns a temporary psychedelic experience into lasting psychological change.
Doses Used in Research
Clinical trials have converged on a therapeutic range of 20 to 30 milligrams of synthetic psilocybin, typically adjusted for body weight (calibrated to a 70-kilogram person). A fixed dose of approximately 25 milligrams is being evaluated in the registration trials that could eventually lead to FDA approval. This is considered a full psychedelic dose, producing intense perceptual and emotional effects for several hours. It is not comparable to what people describe as microdosing.
Side Effects During Treatment
Psilocybin therapy is not side-effect free, though most adverse effects are temporary. A systematic review across multiple clinical trials found that the most common issues were nausea, headache, anxiety, dizziness, and temporary increases in blood pressure. Elevated heart rate was reported by a majority of participants, and nearly half experienced visual perceptual changes, which are expected features of a psychedelic experience rather than unwanted complications.
Nausea typically resolved within an hour. Headaches subsided within 24 hours of the session. Some participants experienced physical discomfort, fatigue, or shifts in mood, though these were generally mild and short-lived. The anxiety that some people feel during dosing is one reason the supervised setting matters so much. Having a trained therapist present helps manage difficult moments that might otherwise become distressing.
Who Should Not Use Psilocybin
Clinical trials exclude people with a history of psychotic disorders like schizophrenia or bipolar I disorder, because psilocybin can potentially trigger psychotic episodes in vulnerable individuals. People currently taking most antidepressants, lithium, antipsychotics, or opioids are also excluded due to drug interactions. Seizure disorders, recent psychedelic use, and certain other medical conditions are additional disqualifiers. Even trials specifically studying bipolar II disorder exclude anyone with a bipolar I diagnosis or psychotic history, reflecting how seriously researchers take these risks.
What About Microdosing?
Microdosing, taking very small amounts of psilocybin that don’t produce a full psychedelic experience, has generated enormous popular interest. The scientific evidence, however, hasn’t kept pace with the enthusiasm. Rigorously controlled trials have so far failed to produce compelling evidence that microdosing works better than a placebo for depression. Some studies found that people in both the microdosing and placebo groups reported similar improvements, suggesting that expectation and belief may account for much of the benefit people describe. More rigorous trials are underway, but as of now, the strongest evidence supports full therapeutic doses in supervised settings, not microdosing on your own.
Lion’s Mane: A Non-Psychoactive Option
Not all mushroom research involves psychedelics. Lion’s mane, a culinary and medicinal mushroom available as a supplement, has drawn attention for its potential mood-related benefits through a completely different mechanism. It appears to stimulate production of a protein called BDNF, which supports the growth and survival of brain cells, somewhat paralleling the neuroplasticity effects of psilocybin but without any psychoactive properties.
A double-blind pilot study in young adults found mood improvements associated with lion’s mane supplementation, and a separate trial in overweight adults reported reductions in depression, anxiety, and sleep problems after eight weeks of daily supplementation at 550 milligrams. These mood improvements were linked to changes in BDNF-related markers. The evidence is still early-stage and based on small studies, so lion’s mane shouldn’t be considered a proven treatment for depression. But for someone interested in mushroom-based approaches who isn’t a candidate for psilocybin therapy, it represents a legal, accessible option with a plausible biological rationale.
Where Things Stand Legally
Psilocybin has been classified as a Schedule I controlled substance in the United States since 1971, meaning it’s illegal to manufacture, possess, or distribute outside of approved research. In 2018 and 2019, the FDA granted psilocybin “Breakthrough Therapy” designation for both treatment-resistant depression and major depressive disorder, a status that speeds up the review process for drugs that show substantial improvement over existing treatments. This designation doesn’t mean approval. It means the FDA considers the early evidence promising enough to fast-track development. A handful of U.S. cities and the state of Oregon have created legal frameworks for supervised psilocybin use, but these operate independently from the federal approval process.